Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 195
- Registration Number
- NCT06836063
Safety, Tolerability, Pharmacokinetics And Pharmacodynamics of SUVN-I6107 In Healthy Participants
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT06705088
- Locations
- 🇺🇸
Clinical Research Site, San Antonio, Texas, United States
Study Evaluating Safety and Efficacy of Ropanicant in MDD Patients
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 41
- Registration Number
- NCT06126497
- Locations
- 🇺🇸
Clinical Innovations, Inc, Bellflower, California, United States
🇺🇸Collaborative Neuroscience Research, LLC, Torrance, California, United States
🇺🇸NRC Research Institute, Orange, California, United States
Expanded Access to SUVN-G3031 (Samelisant) for the Treatment of Subjects With Narcolepsy
- Conditions
- Narcolepsy
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2022-09-23
- Lead Sponsor
- Suven Life Sciences Limited
- Registration Number
- NCT05530447
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
- Conditions
- AgitationAlzheimer's Type Dementia
- Interventions
- Drug: Masupirdine 50 mgDrug: PlaceboDrug: Masupirdine 100 mg
- First Posted Date
- 2022-05-31
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 375
- Registration Number
- NCT05397639
- Locations
- 🇵🇱
Centrum Medyczne Silmedic Sp z o o, Katowice, Slaskie, Poland
🇵🇱Neuro-Medic Janusz Zbrojkiewicz, Katowice, Slaskie, Poland
🇺🇸Ocean Medical Research, Toms River, New Jersey, United States
A Study to Evaluate Safety, and Efficacy of SUVN-G3031 (Samelisant) in Patients With Narcolepsy With and Without Cataplexy
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2025-01-13
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 190
- Registration Number
- NCT04072380
- Locations
- 🇺🇸
Santa Monica Clinical Trials, Los Angeles, California, United States
🇺🇸Southern California Institute for Respiratory Diseases, Inc., Los Angeles, California, United States
🇺🇸St. Francis Medical Institute, Clearwater, Florida, United States
Expanded Access to Provide SUVN-502 for the Treatment of Subjects With Alzheimer's Disease
- Conditions
- Alzheimer DiseaseDementiaCognition Disorders
- First Posted Date
- 2018-06-21
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- Suven Life Sciences Limited
- Registration Number
- NCT03564964
Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-911 in Healthy Subjects
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2018-08-09
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 28
- Registration Number
- NCT03551288
- Locations
- 🇺🇸
IQVIA Phase One Services, LLC, Kansas City, Kansas, United States
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-911 in Healthy Subjects
- First Posted Date
- 2017-05-16
- Last Posted Date
- 2018-05-29
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 64
- Registration Number
- NCT03155503
- Locations
- 🇺🇸
QuintilesIMS Phase 1 Services, LLC, Kansas City, Kansas, United States
A Study to Investigate the Effect of Food, Gender, and Age on the Pharmacokinetic Profile of SUVN-D4010 in Healthy Subjects
- First Posted Date
- 2017-01-25
- Last Posted Date
- 2017-09-25
- Lead Sponsor
- Suven Life Sciences Limited
- Target Recruit Count
- 28
- Registration Number
- NCT03031574
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States